The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

KBC Group NV lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,047.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...

Repare Therapeutics Inc. (NASDAQ:RPTX – Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 1,130,000 ...